Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries

Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries

Objectives We aimed to examine the relationship between access to medicine for cardiovascular disease (CVD) and major adverse cardiovascular events (MACEs) among people at high risk of CVD in high-income countries (HICs), upper and lower middle-income countries (UMICs, LMICs) and low-income countrie...

Full description

Bibliographic Details
Published in:BMJ Global Health
Main Author: Chow C.K.; Nguyen T.N.; Marschner S.; Diaz R.; Rahman O.; Avezum A.; Lear S.A.; Teo K.; Yeates K.E.; Lanas F.; Li W.; Hu B.; Lopez-Jaramillo P.; Gupta R.; Kumar R.; Mony P.K.; Bahonar A.; Yusoff K.; Khatib R.; Kazmi K.; Dans A.L.; Zatonska K.; Alhabib K.F.; Kruger I.M.; Rosengren A.; Gulec S.; Yusufali A.; Chifamba J.; Rangarajan S.; McKee M.; Yusuf S.
Format: Article
Language:English
Published: BMJ Publishing Group 2020
Online Access:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85095810414&doi=10.1136%2fbmjgh-2020-002640&partnerID=40&md5=8b05c5af854bf9aea745059539a75874
Description
Summary:Objectives We aimed to examine the relationship between access to medicine for cardiovascular disease (CVD) and major adverse cardiovascular events (MACEs) among people at high risk of CVD in high-income countries (HICs), upper and lower middle-income countries (UMICs, LMICs) and low-income countries (LICs) participating in the Prospective Urban Rural Epidemiology (PURE) study. Methods We defined high CVD risk as the presence of any of the following: hypertension, coronary artery disease, stroke, smoker, diabetes or age >55 years. Availability and affordability of blood pressure lowering drugs, antiplatelets and statins were obtained from pharmacies. Participants were categorised: group 1-all three drug types were available and affordable, group 2-all three drugs were available but not affordable and group 3-all three drugs were not available. We used multivariable Cox proportional hazard models with nested clustering at country and community levels, adjusting for comorbidities, sociodemographic and economic factors. Results Of 163 466 participants, there were 93 200 with high CVD risk from 21 countries (mean age 54.7, 49% female). Of these, 44.9% were from group 1, 29.4% from group 2 and 25.7% from group 3. Compared with participants from group 1, the risk of MACEs was higher among participants in group 2 (HR 1.19, 95% CI 1.07 to 1.31), and among participants from group 3 (HR 1.25, 95% CI 1.08 to 1.50). Conclusion Lower availability and affordability of essential CVD medicines were associated with higher risk of MACEs and mortality. Improving access to CVD medicines should be a key part of the strategy to lower CVD globally. © 2020 Author(s)
ISSN:20597908
DOI:10.1136/bmjgh-2020-002640

Similar Items

  • Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study
    by: Chow C.K.; Ramasundarahettige C.; Hu W.; AlHabib K.F.; Avezum A., et al.
    Published: (2018)
  • Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: An analysis of the PURE study data
    by: Khatib R.; McKee M.; Shannon H.; Chow C.; Rangarajan S.; Teo K.; Wei L.; Mony P.; Mohan V.; Gupta R.; Kumar R.; Vijayakumar K.; Lear S.A.; Diaz R.; Avezum A.; Lopez-Jaramillo P.; Lanas F.; Yusoff K.; Ismail N.; Kazmi K.; Rahman O.; Rosengren A.; Monsef N.; Kelishadi R.; Kruger A.; Puoane T.; Szuba A.; Chifamba J.; Temizhan A.; Dagenais G.; Gafni A.; Yusuf S.
    Published: (2016)
  • Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data
    by: Attaei M.W.; Khatib R.; McKee M.; Lear S.; Dagenais G.; Igumbor E.U.; AlHabib K.F.; Kaur M.; Kruger L.; Teo K.; Lanas F.; Yusoff K.; Oguz A.; Gupta R.; Yusufali A.M.; Bahonar A.; Kutty R.; Rosengren A.; Mohan V.; Avezum A.; Yusuf R.; Szuba A.; Rangarajan S.; Chow C.; Yusuf S.; O'Donnell M.; Mente A.; Leong D.; Smyth A.; Joseph P.; Islam S.; Zhang M.; Hu W.; Ramasundarahettige C.; Wong G.; Dayal L.; Casanova A.; Dehghan M.; Lewis G.; Aliberti A.; Reyes A.; Zaki A.; Lewis B.; Zhang B.; Agapay D.; Hari D.; Milazzo E.; Ramezani E.; Hussain F.; Shifaly F.; Kay I.; Rimac J.; Swallow J.; Heldman L.; Mushtaha M.; Mushtaha M.; Trottier M.; Aoucheva N.; Kandy N.; Mackie P.; Solano R.; Chin S.; Ramacham S.; Shahrook S.; Trottier S.; Tongana T.; ElSheikh W.; Lindeman J.; McQueen M.; Hall K.; Keys J.; Wang X.; Keneth J.; Devanath A.; Diaz R.; Orlandini A.; Linetsky B.; Toscanelli S.; Casaccia G.; Maini Cuneo J.M.; Rahman O.; Azad A.K.; Rabbani K.A.; Cherry H.M.; Mannan A.; Hassan I.; Talukdar A.T.; Tooheen R.B.; Khan M.U.; Sintaha M.; Choudhury T.; Haque R.; Parvin S.; Oliveira G.B.; Marcilio C.S.; Mattos A.C.; Dejesus J.; Poirier P.; Turbide G.; Auger D.; De Bluts A.L.; Proulx M.C.; Cayer M.; Bonneville N.; Gasevic D.; Corber E.; de Jong V.; Vukmirovich I.; Wielgosz A.; Fodor G.; Pipe A.; Shane A.; Seron P.; Martinez S.; Valdebenito A.; Oliveros M.; Wei L.; Lisheng L.; Chunming C.; Xingyu W.; Wenhua Z.; Hongye Z.; JiaXuan; Bo H.; Yi S.; Jian B.; Xiuwen Z.; Xiaohong C.; Tao C.; Hui C.; Qing D.; Xiaoru C.; Xinye H.; JiaXuan; Jian L.; Juan L.; Xu L.; Bing R.; Wei W.; Yang W.; Jun Y.; Yi Z.; Manlu Z.; Fanghong L.; Jianfang W.; Yindong L.; Yan H.; Liangqing Z.; Baoxia G.; Xiaoyang L.; Shiying Z.; BianRongwen; TianXiuzhen; Dong L.; Di C.; Jianguo W.; Yize X.; Tianlu L.; Peng Z.; Changlin D.; Ning L.; Xiaolan M.; Yuqing Y.; Rensheng L.; Minfan F.; Jing H.; Yu L.; Xiaojie X.; Qiang Z.; Lopez-Jaramillo P.; Lopez P.C.; Garcia R.; Jurado L.J.A.; Gómez-Arbeláez D.; Arguello J.F.; Dueñas R.; Silva S.; Pradilla L.P.; Ramirez F.; Molina D.I.; Cure-Cure C.; Perez M.; Hernandez E.; Arcos E.; Fernandez S.; Narvaez C.; Paez J.; Sotomayor A.; Garcia H.; Sanchez G.; David T.; Rico A.; Mony P.; Vaz M.; Bharathi A.V.; Swaminathan S.; Shankar K.; Kurpad A.V.; Jayachitra K.G.; Kumar N.; Hospital H.A.L.; Deepa M.; Parthiban K.; Anitha M.; Hemavathy S.; Rahulashankiruthiyayan T.; Anitha D.; Sridevi K.; Panwar R.B.; Mohan I.; Rastogi P.; Rastogi S.; Bhargava R.; Kumar R.; Thakur J.S.; Patro B.; Lakshmi P.V.M.; Mahajan R.; Chaudary P.; Vijayakumar K.; Ajayan K.; Rajasree G.; Renjini A.R.; Deepu A.; Sandhya B.; Asha S.; Soumya H.S.; Kelishadi R.; Mohammadifard N.; Heidari H.; Ismail T.S.T.; Ng K.K.; Devi A.; Nasir N.M.; Yasin M.M.; Miskan M.; Rahman E.A.; Arsad M.K.M.; Ariffin F.; Razak S.A.; Majid F.A.; Bakar N.A.; Yacob M.Y.; Zainon N.; Salleh R.; Ramli M.K.A.; Halim N.A.; Norlizan S.R.; Ghazali N.M.; Arshad M.N.; Razali R.; Ali S.; Othman H.R.; Hafar C.; Pit A.; Danuri N.; Basir F.; Zahari S.N.A.; Abdullah H.; Arippin M.A.; Zakaria N.A.; Noorhassim I.; Hasni M.J.; Azmi M.T.; Zaleha M.I.; Hazdi K.Y.; Rizam A.R.; Sazman W.; Azman A.; Khammash U.; Khatib A.; Giacaman R.; Iqbal R.; Afridi A.; Khawaja R.; Raza A.; Kazmi K.; Dans A.; Co H.U.; Sanchez J.T.; Pudol L.; Zamora-Pudol C.; Palileo-Villanueva L.A.M.; Aquino M.R.; Abaquin C.; Cabral M.L.; Zatonski W.; Zatonska K.; Ilow# R.; Ferus M.; Regulska-Ilow B.; Różańska D.; Wolyniec M.; Hersi A.; Kashour T.; Alfaleh H.; Alshamiri M.; Altaradi H.B.; Alnobani O.; Bafart A.; Alkamel N.; Ali M.; Abdulrahman M.; Nouri R.; Kruger A.; Voster H.H.; Schutte A.E.; Wentzel-Viljoen E.; Eloff F.C.; de Ridder H.; Moss H.; Potgieter J.; Roux A.A.; Watson M.; de Wet G.; Olckers A.; Jerling J.C.; Pieters M.; Hoekstra T.; Puoane T.; Tsolekile L.; Sanders D.; Ilow P.; Steyn N.; Peer N.; Mayosi B.; Rayner B.; Lambert V.; Levitt N.; Kolbe-Alexander T.; Ntyintyane L.; Hughes G.; Swart R.; Fourie J.; Muzigaba M.; Xapa S.; Gobile N.; Ndayi K.; Jwili B.; Ndibaza K.; Egbujie B.; Boström K.B.; Lindblad U.; Langkilde P.; Gustavsson A.; Andreasson M.; Snällman M.; Wirdemann L.; Pettersson K.; Moberg E.; Yeates K.; Sleeth J.; Kilonzo K.; Akalin A.A.K.; Calik K.B.T.; Imeryuz N.; Temizhan A.; Alphan E.; Gunes E.; Sur H.; Karsidag K.; Gulec S.; Altuntas Y.; Almahmeed W.; Swidan H.; Darwish E.A.; Hashemi A.R.A.; Al-Khaja N.; Muscat-Baron J.M.; Ahmed S.H.; Mamdouh T.M.; Darwish W.M.; Abdelmotagali M.H.S.; Awed S.O.; Movahedi G.A.; Shaibani H.A.; Gharabou R.I.M.; Youssef D.F.; Nawati A.Z.S.; Salah Z.A.; Abdalla R.F.E.; Shuwaihi S.A.; Omairi M.A.; Cadigal O.D.; Alejandrino R.S.; Chifamba J.; Gwaunza L.; Terera G.; Mahachi C.; Murambiwa P.; Machiweni T.; Mapanga R.
    Published: (2017)
  • Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study
    by: Yusuf S.; Joseph P.; Rangarajan S.; Islam S.; Mente A.; Hystad P.; Brauer M.; Kutty V.R.; Gupta R.; Wielgosz A.; AlHabib K.F.; Dans A.; Lopez-Jaramillo P.; Avezum A.; Lanas F.; Oguz A.; Kruger I.M.; Diaz R.; Yusoff K.; Mony P.; Chifamba J.; Yeates K.; Kelishadi R.; Yusufali A.; Khatib R.; Rahman O.; Zatonska K.; Iqbal R.; Wei L.; Bo H.; Rosengren A.; Kaur M.; Mohan V.; Lear S.A.; Teo K.K.; Leong D.; O'Donnell M.; McKee M.; Dagenais G.
    Published: (2020)
  • Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study
    by: Rosengren A.; Smyth A.; Rangarajan S.; Ramasundarahettige C.; Bangdiwala S.I.; AlHabib K.F.; Avezum A.; Bengtsson Boström K.; Chifamba J.; Gulec S.; Gupta R.; Igumbor E.U.; Iqbal R.; Ismail N.; Joseph P.; Kaur M.; Khatib R.; Kruger I.M.; Lamelas P.; Lanas F.; Lear S.A.; Li W.; Wang C.; Quiang D.; Wang Y.; Lopez-Jaramillo P.; Mohammadifard N.; Mohan V.; Mony P.K.; Poirier P.; Srilatha S.; Szuba A.; Teo K.; Wielgosz A.; Yeates K.E.; Yusoff K.; Yusuf R.; Yusufali A.H.; Attaei M.W.; McKee M.; Yusuf S.
    Published: (2019)